[1] Beck-Sagué C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System[J]. J Infect Dis,1993, 167(5):1247-1251.
[2] Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals:epidemiology, clinical features and susceptibilities[J]. Pediatr Infect Dis J, 2003, 22(8):686-691.
[3] 吴安华,任南,文细毛,等.全国医院感染监控网1998-1999年监测资料分析[J].中华医院感染学杂志,2000,10(6):401-403.
[4] Loeffler J, Stevens DA. Antifungal drug resistance[J]. Clin Infect Dis,2003, 36(Suppl 1):S31-S41.
[5] Klein SA, Hermann S, Dietrich JW, et al. Transplantation related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies[J]. Blood, 2002, 99(6):2270-2271.
[6] Dadachova E, Bryan RA, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection[J]. J Infect Dis, 2006, 193(10):1427-1436.
[7] Dadachova E, Howell RW, Bryan RA, et al. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioirmnunotherapy with alpha-and beta-emitting radioisotopes[J]. J Nucl Med, 2004, 45(2):313-320.
[8] 杨斌,何杨,张玮,等. 99Tc m-抗人粒细胞单克隆抗体对兔炎症的放射免疫显像[J].中华核医学杂志,2002,22(4):228-230.
[9] Shokeen M, Fettig NM, Rossin R. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles[J]. Q J Nucl Med Mol Imaging, 2008, 52(3):267-277.
[10] Rosas AL, Nosanchuk JD, Casadevall A. Passive Immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans Infection[J]. Infect Immun, 2001, 69(5):3410-3412.
[11] Dadachova E, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins[J]. PloS Med, 2006, 3(11):e427.
[12] Rodrigues ML, Travassos LR, Miranda KR, et al. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth[J]. Infect Immun, 2000, 68(12):7049-7060.
[13] Casadevall A, Cleare W, Feldmesser M, et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies[J]. Antimicrob Agents Chemother, 1998, 42(6):1437-1446.
[14] Dadachova E, Casadenall A. Antibodies as delivery vehicles for radioirmnunotherapy of infectious diseases[J]. Expert Opin Drug Deliv, 2005, 2(6):1075-1084.
[15] Dadachova E, Nakouzi A, Bryan RA, et al. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection[J]. Proc Natl Acad Sci USA, 2003, 100(19):10942-10947.